Entrada Therapeutics Inc
TRDA
NASDAQ
Biotechnology
$7.46
USD
+0.01 (+0.13%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $290.08M
Volume 238.0K
Revenue
$4.69M
TTM
-94.1%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-165.78M
TTM
-126.0%
YoY
Operating Cash Flow
$-134.67M
TTM
-8.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.0 | 1.6 | 1.3 | 0.9 | 0.9 |
YoY Growth | -97.9% | -91.8% | -96.5% | -95.7% | -53.9% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 2.0 | 1.6 | 1.3 | 0.9 | 0.9 |
Selling, General & Administrative | 10.9 | 10.3 | 9.6 | 10.1 | 10.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 48.8 | 48.7 | 43.5 | 43.2 | 45.9 |
Operating Income | -46.8 | -47.1 | -42.2 | -42.3 | -45.0 |
EBITDA | -45.8 | -45.8 | -41.3 | -41.5 | -44.1 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.9 | 3.6 | 3.1 | 2.6 | 2.2 |
Income Before Income Taxes | -42.9 | -43.5 | -39.1 | -39.7 | -42.7 |
Income Taxes | 0.2 | 0.7 | 0.1 | 0.0 | 0.0 |
Net Income | -43.1 | -44.1 | -39.2 | -39.7 | -42.8 |
Consolidated Net Income / Loss | -43.1 | -44.1 | -39.2 | -39.7 | -42.8 |
Net Income Attributable to Common Shareholders | -43.1 | -44.1 | -39.2 | -39.7 | -42.8 |
Basic EPS | -$1.04 | -$1.06 | -$0.94 | -$0.95 | -$1.01 |
Diluted EPS | -$1.04 | -$1.06 | -$0.94 | -$0.95 | -$1.01 |
Basic Shares Outstanding | 41.3M | 41.5M | 41.6M | 41.8M | 42.2M |
Diluted Shares Outstanding | 41.3M | 41.5M | 41.6M | 41.8M | 42.2M |